Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raymond P Abratt

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 24, 2007
Lung cancer management in limited resource settings: guidelines for appropriate good careFergus R Macbeth, Raymond P Abratt, Kwan H Cho, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|December 5, 2003
Guidelines for CPD accreditation of the South African Society of Medical OncologyRaymond P Abratt, Richard W Eek, Richard Eele, et al.
Cancer Biotherapy & Radiopharmaceuticals|May 5, 2009
A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancerJózsef Horti, Anders Widmark, Arnulf Stenzl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2006
Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancerRodryg Ramlau, Radj Gervais, Maciej Krzakowski, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2004
An open letter to all members of the IASLCFergus Macbeth, Richard Stephens, Raymond P Abratt, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancerRaymond P Abratt, Jung Sin Lee, Ji Youn Han, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trialRichard H de Boer, Óscar Arrieta, Chih-Hsin Yang, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 24, 2007
Lung cancer management in limited resource settings: guidelines for appropriate good careFergus R Macbeth, Raymond P Abratt, Kwan H Cho, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|December 5, 2003
Guidelines for CPD accreditation of the South African Society of Medical OncologyRaymond P Abratt, Richard W Eek, Richard Eele, et al.
Cancer Biotherapy & Radiopharmaceuticals|May 5, 2009
A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancerJózsef Horti, Anders Widmark, Arnulf Stenzl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2006
Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancerRodryg Ramlau, Radj Gervais, Maciej Krzakowski, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2004
An open letter to all members of the IASLCFergus Macbeth, Richard Stephens, Raymond P Abratt, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancerRaymond P Abratt, Jung Sin Lee, Ji Youn Han, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trialRichard H de Boer, Óscar Arrieta, Chih-Hsin Yang, et al.
Pageof 3